Company Information

Kitov Pharmaceuticals is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov’s veteran team of healthcare and business professionals maintains a proven track record in streamlined end-to-end drug development and approval. Kitov’s flagship combination drug, Consensi™, achieved the primary efficacy endpoints for its Phase III and Phase III/IV clinical trials, and was approved by the U.S. FDA for patients suffering from osteoarthritis pain and hypertension. NT-219, which is developed by Kitov's majority-owned subsidiary, TyrNovo Ltd., is a novel patented small molecule designed to overcome cancer drug resistance that is currently in pre-clinical development. By lowering development risk and cost through fast-track regulatory approval of novel late-stage therapeutics, Kitov plans to deliver rapid ROI and long-term potential to investors, while making a meaningful impact on people’s lives.

Price Data
NASDAQKTOV
Recent News
Jul 30, 2018

Tel Aviv, Israel, July 30, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (Nasdaq: KTOV; TASE: KTOV.TA), an innovative biopharmaceutical company, today announced that it has entered into a Stipulation...

Jun 27, 2018

Tel Aviv, Israel, June 27, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (Nasdaq: KTOV; TASE: KTOV), an innovative biopharmaceutical company, today announced that it will host a business update...

Jun 15, 2018

TEL AVIV, Israel, June 15, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ:KTOV) (TASE:KTOV), an innovative biopharmaceutical company, today announced positive results in a pre-clinical study...

More >


print email